Compare Agilent Technologies Inc (A) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Uranium Energy Corp — how do they compare? Agilent Technologies Inc trades at $129.06 (market cap $37.04B), while Uranium Energy Corp trades at $9.81 (market cap $4.90B). The key difference: Agilent Technologies Inc is far larger — about 7.6× Uranium Energy Corp's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| A | UEC | |
|---|---|---|
Market Cap | $37.04B | $4.90B |
Sector | Health | Energy |
52-Week High | $157.20 | $20.14 |
52-Week Low | $110.24 | $5.92 |
Enterprise Value | $38.59B | $4.41B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
UEC trades at $10.57, down 2.22% today, amid bearish technical signals and weak quarterly results. The stock shows negative profitability with a -513.24% net income margin and has missed earnings expectations in two of the last three quarters. However, analyst sentiment remains strongly positive with 87.5% buy ratings, supported by the company's strategic positioning in uranium production and substantial liquidity of $794 million with no debt.
The outlook is mixed: strong analyst support and nuclear sector tailwinds offer long-term potential, but near-term risks include persistent losses, high valuation multiples, and operational execution challenges. Investors should weigh the company's asset base and market position against its current financial performance and cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
